Cobicistat; Ritonavir/Tenofovir Alafenamide (> 10 mg) Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Cobicistat can increase the risk of damage on your kidneys.
What might happen:
Taking these medicines together may increase the risk of damage to your kidneys.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Let your doctor know if you experience a decrease in the amount of urine you make.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir) US prescribing information. Gilead Sciences, Inc September, 2021.
- 2.Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir) UK summary of product characteristics. Gilead Sciences, Inc March, 2016.
- 3.Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir) Canada prescribing information. Gilead Sciences Canada November, 2015.
- 4.Descovy (emtricitabine and tenofovir alafenamide) US prescribing information. Gilead Sciences, Inc. January, 2022.
- 5.Descovy (emtricitabine, tenofovir alafenamide) Canadian prescribing information. Gilead Sciences Canada, Inc. May 7, 2019.
- 6.Descovy (emtricitabine, tenofovir alafenamide) EMA Summary of Product Characteristics. Gilead Sciences Ireland UC December 10, 2018.
- 7.Aptivus (tipranavir) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. June, 2020.
- 8.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents Living with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats- new-guidelines June 13, 2021.
- 9.Sax PE, Wohl D, Yin MT, Post F, DeJesus E, etal. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015 Jun 27;385(9987):2606-15.
- 10.FDA (US Food and Drug Administration). CDER Application number: 207561 Genvoya Clinical Pharmacology and Biopharmaceutics Reviews. accessed at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207561Orig1s000Cli nPharmR.pdf November 5, 2015.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.